Masashi Takano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Masashi Takano has a total of 359 co-authors. Here are the top co-authors by number of shared publications:
- Morikazu Miyamoto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
15 shared publications Kenichi Furuya
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Japan
12 shared publications- Hiroaki Soyama
Department of Obstetrics and Gynecology, Takanohara Central Hospital
11 shared publications Yoshihiro Kikuchi
Ohki Memorial Kikuchi Cancer Center for Women, Tokorozawa, Japan
11 shared publicationsMorikazu Miyamoto
National Defense Medical College
10 shared publicationsTomoko Goto
Department of Obstetrics and Gynecology, National Defense Medical College Hospital, Tokorozawa, Saitama 359‑8513, Japan
10 shared publications
Latest Publications
- Open Access
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- 9 April 2026
- Published by Wiley in Cancer Reports
- Vol. 9 (4) , e70535
Open AccessEstablishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor‐Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis
Background: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor‐infiltrating lymphocytes (TILs) based on artificial intelligence (AI). Methods: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin‐stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm 2 ) in the annotated area was calculated using AI. Patients were classified into the High‐TIL and Low‐TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)‐related proteins were evaluated using immunohistochemical staining. Results: A total of 659 patients were included: 346 (52.5%) in the High‐TIL group and 313 (47.5%) in the Low‐TIL group. MMR deficiency was observed more frequently in the High‐TIL group than in the Low‐TIL group ( p < 0.01). Progression‐free survival (PFS) and overall survival (OS) were better in the High‐TIL group than in the Low‐TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43–0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33–0.86); p = 0.01). Conclusion: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (6)
Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology
Shoji T, et al. J Gynecol Oncol. 2026 ;37:e150. https://doi.org/10.3802/jgo.2026.37.e150
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (6)
Open AccessGuidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer: 2025 edition by the Japan Society of Gynecologic Oncology
Shoji T, et al. J Gynecol Oncol. 2026 ;37:e150. https://doi.org/10.3802/jgo.2026.37.e150
- Open Access
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Cesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- 1 January 2026
- Published by Wiley in Obstetrics and Gynecology International
- Vol. 2026 (1)
Open AccessCesarean Section at 38 Gestational Weeks for Placenta Previa was Associated With Improved Neonatal Outcomes Without an Apparent Increase in Maternal Risks: A Historical Control Study
Background and Aims: The optimal timing of cesarean delivery in women with placenta previa (PP) remains controversial because earlier delivery may reduce maternal risks, whereas later delivery may improve neonatal outcomes. This study aimed to evaluate whether delaying planned cesarean section (CS) until 38 gestational weeks was associated with improved neonatal outcomes without increasing maternal risks in women with PP who remain clinically stable. Methods: This historical control study included women with singleton pregnancies complicated by PP who underwent CS at a single tertiary center between 2015 and 2024. Planned CS was scheduled at 38 +0 to 38 +6 gestational weeks between 2022 and 2024 and at 36 +0 to 37 +6 gestational weeks between 2015 and 2022. Women who underwent emergency CS or developed obstetric complications, including antepartum hemorrhage or threatened preterm labor, were excluded from the primary analysis. Women who underwent planned CS at the scheduled gestational weeks were assigned to Group A (38‐week group) and Group B (36–37‐week group). Maternal and neonatal outcomes were compared between the groups. Results: Of the 204 eligible women, 29 were included in Group A and 81 in Group B. Maternal outcomes, including blood loss, operation time, and rates of severe complications, were comparable between the groups. In contrast, neonatal outcomes were improved in Group A, with higher birthweight and lower rates of neonatal hospitalization and hypoglycemia. Most obstetric complications occurred before 36 gestational weeks in both periods. Conclusion: Delaying planned CS until 38 gestational weeks in clinically stable women with PP was associated with improved neonatal outcomes without an apparent increase in maternal risks or emergency CS. These findings support further investigation of the optimal timing of delivery in women with PP.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (4)
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial
Takahashi Y, et al. J Gynecol Oncol. 2024 Jan;35:e37. https://doi.org/10.3802/jgo.2024.35.e37
- 1 January 2024
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 35 (4)
Open AccessPrevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial
Takahashi Y, et al. J Gynecol Oncol. 2024 Jan;35:e37. https://doi.org/10.3802/jgo.2024.35.e37
- Open Access
- 21 June 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (9) , 3041-3045
Lymphoscintigraphy with single-photon emission computerized tomography/computed tomography for evaluating lymphatic leakage following pelvic and para-aortic lymphadenectomy
- 21 June 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (9) , 3041-3045
Open AccessLymphoscintigraphy with single-photon emission computerized tomography/computed tomography for evaluating lymphatic leakage following pelvic and para-aortic lymphadenectomy
- 1 August 2021
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 90, 26-31
Pre-stroke habitual prolonged sleep as a predictor for post-stroke sleep quality, stroke-related quality of life, and lifestyle values
- 1 August 2021
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 90, 26-31
Pre-stroke habitual prolonged sleep as a predictor for post-stroke sleep quality, stroke-related quality of life, and lifestyle values
- Open Access
- 1 May 2021
- Published by Elsevier in Redox Biology
- Vol. 41, 101926
On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity
- 1 May 2021
- Published by Elsevier in Redox Biology
- Vol. 41, 101926
Open AccessOn-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity
- 6 March 2021
- Published by Springer Nature
- p. 71-78
Tailor-Made Therapy According to Genetic Alteration in Epithelial Ovarian Cancers
- 6 March 2021
- Published by Springer Nature
- p. 71-78
Tailor-Made Therapy According to Genetic Alteration in Epithelial Ovarian Cancers